Yuming Chen
About Yuming Chen
Yuming Chen is the Associate Director at Bristol-Myers Squibb, leading analytical strategy for 12 commercial small molecule projects and supporting various regulatory filings.
Professional Background
Yuming Chen is the Associate Director at Bristol-Myers Squibb. His professional journey includes pivotal roles at Celgene, AbbVie, Hisun Pharmaceuticals USA, Forest Laboratories, and Covidien. Starting his career as a Sr. Research Chemist at Covidien from 2007 to 2010, he moved on to become a Research Scientist at Forest Laboratories from 2010 to 2014. He then served as Executive Director of Analytical Sciences at Hisun Pharmaceuticals USA for one year before working as Sr. Scientist II/ Analytical Functional Lead at AbbVie from 2015 to 2018. Most recently, he was a Sr. Manager at Celgene from 2018 to 2020.
Current Role at Bristol-Myers Squibb
As the Associate Director at Bristol-Myers Squibb, Yuming Chen leads the analytical strategy for 12 commercial small molecule projects. He is responsible for supporting life cycle regulatory filings, including rest-of-world filings, prior approval submissions, follow-up measures, post-approval commitments, and post-approval changes. Additionally, he plays a significant role in integrating multiple functions into the new organizational structure at the company.
Analytical Chemistry Expertise
Yuming Chen has cultivated a deep expertise in analytical chemistry. He studied at Auburn University where he achieved a Ph.D. in Analytical Chemistry, completing his studies in 2004. His extensive experience includes working in highly matrixed environments, coordinating analytical development, regulatory CMC, multiple QA functions, manufacturing and QC sites, and various country-specific teams. His technical background is further strengthened by his postdoctoral studies at the Icahn School of Medicine at Mount Sinai.
Educational Background
Yuming Chen's educational background is distinguished by his Ph.D. in Analytical Chemistry from Auburn University, which he earned in 2004. Before that, he studied at Peking University. He also conducted postdoctoral research at the Icahn School of Medicine at Mount Sinai from 2005 to 2007. This education laid a strong foundation for his subsequent career in pharmaceutical and analytical sciences.